Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Completed · Phase 3

Conditions studied: Kidney Cancer

In brief

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. It is not yet known which regimen of interleukin-2 is most effective for kidney cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of interleukin-2 in treating patients who have metastatic kidney cancer.

Key facts

Study ID

NCT00018941

Run by

National Cancer Institute (NCI)

Starts

1991-04-01

Expected to finish

2003-05-01

Last updated by the study team

2013-06-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Surgery Branch — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.